Claims
- 1. A 2,3-dihydrobenzofuran derivative represented by formula (1) or a salt thereof: ##STR14## wherein R.sup.1 represents a hydrogen atom or a lower alkyl group; n is an integer of from 2 to 6; A represents a carbonyl group or a sulfonyl group; R.sup.2 represents a hydrogen atom, a halogen atom, a lower alkyl group which is unsubstituted or substituted with at least one halogen atom, a lower alkoxy group, a hydroxyl group, a nitro group, or a cyano group; and * represents an asymmetric carbon atom.
- 2. A method for producing a 2,3-dihydrobenzofuran derivative represented by formula (1) or a salt thereof: ##STR15## wherein R.sup.1 represents a hydrogen atom or a lower alkyl group; n is an integer of from 2 to 6; A represents a carbonyl group or a sulfonyl group; R.sup.2 represents a hydrogen atom, a halogen atom, a lower alkyl group which is unsubstituted or substituted with at least one halogen atom, a lower alkoxy group, a hydroxyl group, a nitro group, or a cyano group; and * represents an asymmetric carbon atom, which comprises reacting a compound represented by formula (2): ##STR16## wherein * represents an asymmetric carbon atom; n is an integer of from 2 to 6; and R.sup.11 represents an amino-protecting group or a lower alkyl group,
- with a compound represented by formula (3): ##STR17## wherein R.sup.2 represents a hydrogen atom, a halogen atom, a lower alkyl group which is unsubstituted or substituted with at least one halogen atom, a lower alkoxy group, a hydroxyl group, a nitro group, or a cyano group; A represents a carboxyl group or a sulfonyl group; and X represents a leaving atom or group,
- wherein when R.sup.11 in formula (2) is an amino-protecting group, a product obtained by the reaction of said compound represented by formula (2) with said compound represented by formula (3) is subsequently subjected to a treatment for removing said amino-protecting group so that a hydrogen atom is substituted therefor.
- 3. A pharmaceutical composition for treating a serotonergic neuron-related disease, which comprises, as an active ingredient, a 2,3-dihydrobenzofuran derivative represented by formula (1) or a salt thereof: ##STR18## wherein R.sup.1 represents a hydrogen atom or a lower alkyl group; n is an integer of from 2 to 6; A represents a carbonyl group or a sulfonyl group; R.sup.2 represents a hydrogen atom, a halogen atom, a lower alkyl group which is unsubstituted or substituted with at least one halogen atom, a lower alkoxy group, a hydroxyl group, a nitro group, or a cyano group; and * represents an asymmetric carbon atom.
- 4. A method for treating a serotonergic neuron-related disease, which comprises administering to a patient suffering from a serotonergic neuron-related disease a pharmaceutical composition comprising a therapeutically effective amount of a 2,3-dihydrobenzofuran derivative represented by formula (1) or a non-toxic salt thereof: ##STR19## wherein R.sup.1 represents a hydrogen atom or a lower alkyl group; n is an integer of from 2 to 6; A represents a carbonyl group or a sulfonyl group; R.sup.2 represents a hydrogen atom, a halogen atom, a lower alkyl group which is unsubstituted or substituted with at least one halogen atom, a lower alkoxy group, a hydroxyl group, a nitro group, or a cyano group; and * represents an asymmetric carbon atom.
- 5. The derivative or the salt thereof according to claim 1, wherein n is 4.
- 6. The derivative or the salt thereof according to claim 1, wherein R.sup.1 represents hydrogen.
- 7. The derivative or the salt thereof according to claim 1, wherein R.sup.1 represents a methyl or ethyl group.
- 8. The pharmaceutical composition according to claim 3, further comprising an excipient.
- 9. The pharmaceutical composition according to claim 3, further comprising a diluent.
- 10. The pharmaceutical composition according to claim 9, wherein said composition is in the form of an aqueous solution.
- 11. The method according to claim 4, wherein said disease is selected from the group consisting of anxiety, depression, high blood pressure and emeses.
- 12. The method according to claim 11, wherein said disease is emeses.
- 13. The derivative or the salt thereof according to claim 1, wherein n is 4 and A represents a carbonyl group.
- 14. The derivative or the salt thereof according to claim 1, wherein n is 4 and R.sup.2 represents a hydrogen atom or a fluorine atom.
- 15. The derivative or the salt thereof according to claim 1, wherein n is 4 and R.sup.2 represents a chlorine atom, a bromine atom, a lower alkyl group which is unsubstituted or substituted with at least one halogen atom, a lower alkoxy group, a hydroxyl group, a nitro group, or a cyano group with a proviso that R.sup.2 is bound to the benzene ring at a 3-position thereof.
- 16. The derivative or the salt thereof according to claim 1, wherein n is 4 and R.sup.2 represents a methyl or methoxy group.
- 17. (-)-2-{N-(4-benzoylaminobutyl)}aminomethyl-2,3-dihydrobenzo�b!furan or a salt thereof.
- 18. A derivative selected from the group consisting of 2-{N-(4-benzoylaminobutyl)}aminomethyl-2,3-dihydrobenzo�b!furan, 2-{N-(4-benzenesulfonamidobutyl)}aminomethyl-2,3-dihydrobenzo�b!furan, 2,3-dihydro-2-�N-{4-(3-methylbenzoylamino)butyl}!aminomethylbenzo�b!furan, 2,3-dihydro-2-�N-{4-(3-methoxybenzoylamino)butyl}!aminomethylbenzo�b!furan, 2,3-dihydro-2-�N-{4-(2-fluorobenzoylamino)butyl}!aminomethylbenzo�b!furan, 2,3-dihydro-2-�N-{4-(3-fluorobenzoylamino)butyl}!aminomethylenzo�b!furan, 2,3-dihydro-2-�N-{4(4-fluorobenzoylamino)butyl}!aminomethylbenzo�b!furan, (+)-2-{N-(4-benzoylamino)butyl}aminomethyl-2,3-dihydrobenzo�b!furan, 2-{N-(3-benzoylaminopropyl)}aminomethyl-2,3-dihydrobenzo�b!furan, 2-{N-(4-benzoylaminobutyl)-N-methyl}aminomethyl-2,3-dihydrobenzo�b!furan and 2-(N-(4-benzoylaminobutyl)-N-ethyl}aminomethyl-2,3-dihydrobenzo�b!furan, or a salt thereof.
- 19. A derivative selected from the group consisting of 2,3-dihydro-2-�N-{4-(2-methylbenzoylamino)butyl}!aminomethylbenzo�b!furan, 2,3-dihydro-2-�N-{4-(4-methylbenzoylamino)butyl}!aminomethylbenzo�b!furan, 2,3-dihydro-2-�N-{4-(2-methoxybenzoylamino)butyl}!aminomethylbenzo�b!furan, 2,3-dihydro-2-�N-{4-(4-methoxybenzoylamino)butyl}!aminomethylbenzo�b!furan, 2,3-dihydro-2-�N-{4-(2-trifluoromethylbenzoylamino)butyl}!aminomethylbenzo�b!furan, 2,3-dihydro-2-�N-{4-(3-trifluoromethylbenzoylamino)butyl}!aminomethylbenzo�b!furan, 2,3-dihydro-2-�N-{4-(4-trifluoromethylbenzoylamino)butyl}!aminomethylbenzo�b!furan, 2,3-dihydro-2-�N-{4-(3-nitrobenzoylamino)butyl}!amino-methylbenzo�b!furan, 2,3-dihydro-2-�N-{4-(3-cyanobenzoylamino)butyl}!aminomethylbenzo�b!furan, 2-{N-(2-benzoylaminoethyl)}aminomethyl-2,3-dihydrobenzo�b!furan, 2-�N-{2-(3-methylbenzoylamino)ethyl}!aminomethyl-2,3-dihydrobenzo�b!furan, 2-�N-{2-(4-fluorobenzoyl)aminoethyl}!aminomethyl-2,3-dihydrobenzo�b!furan, 2-�N-{3-(4-fluorobenzoylamino)propyl}!-aminomethyl-2,3-dihydrobenzo�b!furan, 2-{N-(3-benzoylaminopropyl)-N-methyl}aminomethyl-2,3-dihydrobenzo�b!furan, 2,3-dihydro-2-�N-{4-(4-fluorobenzenesulfonylamino)butyl}!aminomethylbenzo�b!furan, 2,3-dihydro-2-�N-{4-(3-nitrobenzenesulfonylamino)butyl}!aminomethylbenzo�b!furan and 2,3-dihydro-2-�N-{4-(2-hydroxy-benzoylamino)butyl}!aminomethylbenzo�b!furan, or a salt thereof.
- 20. The method according to claim 2, wherein said derivative or a salt thereof is (-)-2-{N-(4-benzoylaminobutyl)}aminomethyl-2,3-dihydrobenzo�b!furan or a salt thereof.
- 21. The pharmaceutical composition according to claim 3, wherein said derivative or a salt thereof is (-)-2-{N-(4-benzoylaminobutyl)}aminomethyl-2,3-dihydrobenzo�b!furan or a salt thereof.
- 22. The method according to claim 4, wherein said derivative or a salt thereof is (-)2-{N-(4-benzoylaminobutyl)}aminomethyl-2,3-dihydrobenzo�b!furan or a salt thereof.
Priority Claims (2)
Number |
Date |
Country |
Kind |
5-003067 |
Jan 1993 |
JPX |
|
5-202365 |
Aug 1993 |
JPX |
|
Parent Case Info
This application is a continuation of application Ser. No. 08/454,291 filed on Jun. 15, 1995, now abandoned.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4847254 |
Boegesoe et al. |
Jul 1989 |
|
5134140 |
Stack |
Jul 1992 |
|
5286735 |
Bonnaud et al. |
Feb 1994 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
0538080 |
Apr 1993 |
EPX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
454291 |
Jun 1995 |
|